Pituitary neuroendocrine tumors: from old treatments to innovations, from efficacy to tolerance, from benignity to carcinomas, where do we stand now?

Best Pract Res Clin Endocrinol Metab. 2022 Dec;36(6):101717. doi: 10.1016/j.beem.2022.101717. Epub 2022 Nov 12.

Authors

Frederic Castinetti¹, Gerald Raverot²

Affiliations

¹ Aix Marseille University, Marseille Medical Genetics, INSERM U1251 and Assistance Publique Hopitaux de Marseille, La Conception Hospital, Department of Endocrinology, Marseille, France. Electronic address: Frederic.CASTINETTI@ap-hm.fr.
² Inserm U1052, CNRS UMR5286, Claude Bernard Lyon 1 University, Cancer Research Center of Lyon, Lyon, France. Electronic address: gerald.raverot@chu-lyon.fr.

PMID: 36460564
DOI: 10.1016/j.beem.2022.101717

No abstract available

Publication types

Editorial

MeSH terms

Carcinoma*
Carcinoma, Neuroendocrine* / pathology
Humans
Neuroendocrine Tumors* / therapy
Pituitary Diseases*
Pituitary Gland / pathology
Pituitary Neoplasms* / therapy